To accurately diagnose pharyngitis caused by Group A Streptococcus (GAS) due to increasing incidence and prevalence globally.
Annually, 616 million people have GAS pharyngitis, more than 18.1 million people develop severe GAS disease and more than 517,000 people die due to severe GAS disease.1
Reduce overuse of antibiotics for the treatment of pharyngitis
Based on recent literature 37% of children presenting with pharyngitis tested positive for GAS, however 56% of visits were associated with antibiotic prescriptions. Similarly, 18% of adults presenting with pharyngitis caused by GAS, but 72% were treated with antibiotics.2
Cepheid provides on-demand testing for Group A Strep in as soon as 18 minutes.*
Careful selection of the target gene produces quality results.
Delivering accurate and timely results optimizes fast treatment decisions and eliminates the need to perform culture confirmation of negative results.
Accurate diagnosis of GAS supports antimicrobial stewardship and may reduce the amount of patients inappropriately prescribed antibiotics.
Gain testing efficiencies and reduce costs by eliminating culture confirmation testing.3
Reduce the risk of GAS complications such as rheumatic fever and glomerulonephritis.
Improve patient satisfaction with quicker time to result and appropriate prescriptions.